Real-world data on new users of atypical antipsychotics: characterisation, prescription patterns, healthcare costs and early cardio-metabolic occurrences from a large Italian database.

Purpose: To describe new users of atypical antipsychotics (APs) in terms of sociodemographic characteristics, cardio-metabolic risk profile, prescription patterns, healthcare costs and cardio-metabolic events over the 24 months after treatment initiation. Methods: Atypical AP new users were selected...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Clinical Pharmacology Vol. 76; no. 9; pp. 1301 - 1311
Autores principales: Piccinni, Carlo, Dondi, Letizia, Ronconi, Giulia, Calabria, Silvia, Esposito, Immacolata, Pedrini, Antonella, Maggioni, Aldo P., Barbui, Corrado, Martini, Nello
Formato: research tables/charts Journal Article
Publicado: Springer Nature Sep2020
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=145048858&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 145048858
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00316970
        NP9
      jtl: European Journal of Clinical Pharmacology
      issn: 00316970
      maglogo: N
    pubinfo:
      dt: Sep2020
      vid: 76
      iid: 9
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        145048858
        144150264
        145048858
        145048858
        10.1007/s00228-020-02899-9
        145048858
      ppf: 1301
      ppct: 10
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Real-world data on new users of atypical antipsychotics: characterisation, prescription patterns, healthcare costs and early cardio-metabolic occurrences from a large Italian database.
      aug:
        au:
          Piccinni, Carlo
          Dondi, Letizia
          Ronconi, Giulia
          Calabria, Silvia
          Esposito, Immacolata
          Pedrini, Antonella
          Maggioni, Aldo P.
          Barbui, Corrado
          Martini, Nello
        affil: Fondazione ReS (Ricerca e Salute)–Research and Health Foundation, Via Magnanelli 6/3, Casalecchio di Reno, 40033, Bologna, Italy
      sug:
        subj:
          Antipsychotic Agents Therapeutic Use
          Prescribing Patterns
          Health Care Costs Italy
          Cardiovascular Risk Factors
          Metabolic Diseases Risk Factors
          Human
          Female
          Adolescence
          Adult
          Middle Age
          Aged
          Aged, 80 and Over
          Italy
          Comparative Studies
          Matched Case Control
          Descriptive Statistics
          Adolescent: 13-18 years
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Aged: 65+ years
          Aged, 80 & over
          Female
      ab: Purpose: To describe new users of atypical antipsychotics (APs) in terms of sociodemographic characteristics, cardio-metabolic risk profile, prescription patterns, healthcare costs and cardio-metabolic events over the 24 months after treatment initiation. Methods: Atypical AP new users were selected from the ReS database and grouped into three: patients already affected by cardio-metabolic diseases (group A), patients without these clinical conditions but with predisposing conditions (group B) and patients without cardio-metabolic diseases and predisposing conditions (group C). Annual prescription patterns and healthcare costs were analysed. Subjects of groups B and C were matched with controls to compare the occurrences of cardio-metabolic events over 24 months. Results: Thirty-two thousand thirty-four new users of atypical APs were selected (median age 69). The 22.3% had cardio-metabolic diseases, 14.8% had predisposing conditions and 62.9% had none of these. The 99.3% received monotherapy. The mean annual cost per patient was €2785, and the median cost was €1108. After 24 months, a cardio-metabolic event occurred in 11.5% of group B vs. 8.7% of the controls (p <.01), and in 5.0% of group C vs. 2.1% of the controls (p <.01). Conclusion: Patients treated with atypical AP were on average old and, in a non-negligible amount, with cardio-metabolic disease or predisposing conditions. New users of atypical APs showed a significantly higher likelihood to develop a cardio-metabolic event early after treatment initiation.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N